The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2021 | Antibiotics impact outcomes with pembrolizumab in NSCLC patients
David Pinato, MD, MRes, PhD, Imperial College London, London, UK, outlines the impact of host determinants on response to immunotherapy in patients with non-small cell lung cancer (NSCLC), highlighting PD-L1 expression as a biomarker for pembrolizumab response. Dr Pinato also discusses the findings of a study which reported that antibiotic therapy has a significant negative impact on pembrolizumab monotherapy outcomes, but not on chemotherapy outcomes, in patients with NSCLC. This interview took place during the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.
Disclosures
David Pinato, MD, MRes, PhD, has received lecture fees from ViiV Healthcare and Bayer Healthcare; has received travel expenses from BMS and Bayer Healthcare; has received consulting fees from Mina Therapeutics, EISAI, Roche and Astra Zeneca; and has received research funding (to the institution) from MSD and BMS.
